Portfolio Update

Finsbury Worldwide Pharm Tst PLC 04 October 2004 4 October 2004 FINSBURY WORLDWIDE PHARMACEUTICAL TRUST PLC (the 'Company') QUARTERLY STATEMENT OF INVESTMENTS In compliance with the Listing Rules - Chapter 21 Investment Entities (I)(ii), the Company discloses the following: • Investments valuing greater than 5% of the Company's gross assets comprise the following: Company Name Value of Investment at % of Total 30 September 2004 Portfolio Assets Genzyme Corp General Division 12,008,510 5.35 Novartis 11,910,115 5.30 • The ten largest investments held by the Company comprise the following: Company Name Value of Investment at % of Total 30 September 2004 Portfolio Assets Genzyme Corp General Division 12,008,510 5.35 Novartis 11,910,115 5.30 Genentech Inc 11,006,991 4.90 Pfizer 10,986,295 4.89 Schering-Plough Corporation 10,530,242 4.69 Amgen 10,495,564 4.67 Altana AG 10,365,352 4.62 Given Imaging 10,313,503 4.59 Medimmune Inc 9,600,232 4.27 Lilly (Eli) & Company 9,291,039 4.14 - ENDS - For further information please contact: Tracey Lago, Company Secretary Close Finsbury Asset Management Limited Telephone: 020 7426 6219 This information is provided by RNS The company news service from the London Stock Exchange
UK 100

Latest directors dealings